Delivering Innovated Care In The Clinic: Innovations Made In The Clinic Have Been Transformative In Terms Of Improving The Quality & Value Of Care For Patients

Delivering Innovated Care In The Clinic: Innovations Made In The Clinic Have Been Transformative In Terms Of Improving The Quality & Value Of Care For Patients

Annual-Meeting

6 months
226 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Debra Patt MD @dapattmd Of US Oncology Research Discusses Delivering Innovated Care In The Clinic: Innovations Made In The Clinic Have Been Transformative In Terms Of Improving The Quality & Value Of Care For Patients. Investigators from McKesson, The US Oncology Network (The Network) and US Oncology Research will showcase detailed findings from more than 60 studies during the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, being held in Chicago from May 31 to June 4, 2019, will bring together more than 32,000 oncology professionals from around the globe. ASCO continues to serve as a meaningful platform for community oncologists to share learnings and real-world evidence that advance therapies and care practices to foster the utmost care for oncology patients, said Michael Seiden, MD, PhD, president, The US Oncology Network. As therapies continue to improve and become more personalized to the individuals particular cancer, staying engaged in cutting-edge clinical trials and sharing our findings with forward-thinking colleagues in the oncology community help oncologists and researchers in The Network contribute in meaningful ways in the fight against cancer. Key study presentations during this years conference will include research on sarcoma, non-small cell metastatic lung cancer, hematologic malignancies (such as leukemia, myelodysplastic syndromes and allotransplant), developmental immunotherapy and tumor immunobiology, non-Hodgkin lymphoma, developmental therapeutics and tumor biology and genitourinary (non-prostate) cancer. Some of these studies utilized high-quality real-world data captured from iKnowMed?, McKessons oncology practice electronic health record (EHR) system that was named the top-ranked EHR platform for oncologists and hematologists for the eighth year in a row by Black Book Research. Through McKessons Data, Evidence and Insights business, this rich, regulatory-grade data is leveraged to support biopharmaceutical real-world evidence needs. The increased role of real-world evidence is ever important in improving patient outcomes for individuals battling cancer, said Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences. Furthermore, regulatory agencies now consider these data sets as a part of a bigger picture when evaluating a therapeutic filing, especially in areas with unmet needs. Additionally, at the event, Debra Patt, MD, MPH, MBA, of Texas Oncology, a practice in The US Oncology Network, will officially be recognized with her designation of Fellow of the American Society of Clinical Oncology (FASCO). The designation honors the most active ASCO volunteers. Dr. Patt is a long-standing member of the community oncologist community with more than 20 years of experience. She also serves as editor-in-chief of JCO Clinical Cancer Informatics and is a member of ASCOs Nominating Committee, White and Brown Bagging Committee, Clinical Practice Committee (CPC) Physician Compensation Workgroup, MACRA Speakers Group and CPC Payment Reform Implementation Workgroup. From harnessing data- and evidence-driven insights to breakthrough genetics-based scientific research, the pace of advancement in cancer treatment is more robust now than at any time in my career, said Dr. Patt. New, more personalized treatments are revolutionizing oncology and delivering profound benefits to patients. We have witnessed the first cancer therapies approved by the FDA that have included real-world evidence. ASCO provides us with a glimpse of the future and the promise it holds for our patients. Im honored to be named a recognized Fellow and to be able to bring real-world perspectives from community-based oncology to this outstanding organization. The full schedule of affiliated data presentations, including location information, can be found here. For more information or to be put in touch with a trial investigator, contact Claire Crye at 281.825.9927 or Edie DeVine at 209.814.9564. Please visit Booth #4089 in the ASCO Exhibit Hall. About US Oncology Research US Oncology Research draws from a network of more than 1,000 experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and more than 155 locations, managing about 300 active trials at any given time. For the past 20 years, physicians in the research network have enrolled more than 77,000 patients in over 1,600 trials and have played a role in more than 85 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. US Oncology Research is supported by McKesson Corporation. About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 1,200 independent physicians deliver value-based, integrated care to patients close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere. About McKesson Corporation McKesson Corporation, currently ranked 7th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, healthcare technology, community oncology and specialty care. McKesson partners with life sciences companies, manufacturers, providers, pharmacies, governments and other healthcare organizations to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities to improve patient care in every setting one product, one partner, one patient at a time. McKesson has been named a Most Admired Company in the healthcare wholesaler category by FORTUNE, a Best Place to Work by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com.
Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 19 hours
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 20 hours
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 20 hours
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
11 Views
ash 1 day
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 1 day
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
ash 1 day
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 2 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 2 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 2 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 2 days